Phase 4 Psoriatic Arthritis Trial, Recruiting NCT07141004 Sponsor: Johnson & Johnson Private Limited Condition: Psoriatic Arthritis
Back to Psoriatic Arthritis

Phase 4 Psoriatic Arthritis Trial, Recruiting

NCT07141004
Recruiting Phase 4

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You have been formally diagnosed with active psoriatic arthritis (a type of arthritis linked to psoriasis), confirmed using a standard medical checklist, and your arthritis affects at least one specific pattern of joints in your body.
  • A blood test has shown you do not have rheumatoid factor (a marker sometimes found in other types of arthritis).
  • You still have swollen or tender joints despite trying standard treatments at the highest recommended dose for at least 3 months — this could include medications like methotrexate, apremilast, or anti-inflammatory painkillers, and you may or may not have tried biologic treatments before.
  • You have no history of tuberculosis (TB), no symptoms of TB, and no recent close contact with someone who has TB.
  • Recent TB tests (a blood test and a skin test) taken within 6 weeks before starting the study have come back negative, or if positive, a doctor has confirmed you do not have active TB and you have started treatment for inactive TB.
  • A chest X-ray taken within the last 3 months shows no signs of active or past TB.
  • You are generally in stable health based on a physical exam, medical history, vital signs, and a heart tracing (ECG).
  • If you are a woman who could become pregnant, a blood pregnancy test at the start of the study has come back negative.

Who may not be able to join:

  • You have a history of certain types of infections involving granulomas (clusters of inflamed cells), whether past or currently inactive (confirm with trial site).
  • You have a known allergy or serious sensitivity to guselkumab (the study drug) or any of its ingredients.
  • You have had a serious infection, been hospitalised for an infection, or received antibiotic treatment through a drip within the last 2 months.
  • You have been diagnosed with any cancer, have a history of cancer, or have had a condition involving abnormal growth of lymph cells.
  • You have received, or are planning to receive, a live vaccine (such as certain flu, shingles, or travel vaccines) within 3 months before starting the trial, during the trial, or within 6 months after your last dose of the study drug.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 28 July 2026
Phase 4 trials study a drug that has already been approved, monitoring long-term safety and effectiveness in real-world use.

Contact this trial

Principal Investigator: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC

Phone: 844-434-4210

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Phase 4
Sponsor
Johnson & Johnson Private Limited
Registry
ClinicalTrials.gov
Start date
12 August 2025
Est. completion
5 June 2027

Where this trial is recruiting

🇮🇳 India

Primary endpoints

Number of Participants With Adverse Events (AEs); Number of Participants With Serious Adverse Events (SAEs)

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov